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Abstract	
Breast	cancer	is	the	second	leading	cause	of	deaths	among	women,	as	about	one	in	eight	
women	in	the	US	will	develop	invasive	breast	cancer	during	their	lifetime.	After	the	diagnosis	of	
breast	cancer,	chemotherapy	is	the	commonly	prescribed	first	line	of	treatment.	In	the	recent	
past,	research	has	shown	that	molecular	diagnostic	tests	have	revealed	that	about	20%	of	the	
tumors	carry	the	HER-2	mutation	on	cell	surface,	which	can	be	treated	with	the	drug	Herceptin,	
or	trastuzumab,	improving	cancer	free	survival	rates	from	71.9%	to	84.2%	in	five	years.	
However,	in	spite	of	the	observed	increase	in	survival	rates,	the	question	of	economic	value	
produced	by	adding	Herceptin	to	the	chemotherapy	remains	an	open	question.	We	developed	
a	model	to	analyze	the	economic	benefits	of	using	molecular	diagnostics	to	reveal	actionable	
clinical	alterations.	We	used	cancer	registry	incidence	data	from	the	Surveillance,	Epidemiology,	
and	End	Results	(SEER)	program	to	compare	the	incidence	rates	and	survival	years	per	patient	
in	a	broad	population.	The	results	were	incorporated	into	an	economic	model	to	predict	
benefits	derived,	in	terms	of	cost	savings,	by	the	breast	cancer	patients.	Specifically,	we	
projected	per	patient	life	years	saved	by	adding	Herceptin	to	the	chemotherapy.	Using	
conservative	estimates	for	the	dollar	value	of	each	life	year	saved,	which	stands	at	$100,000	in	
2016	dollars,	total	savings	from	adding	Herceptin	to	chemotherapy	were	$36,925	per	patient.	
Even	stretching	the	cost	estimates	does	not	change	the	general	results.	This	model,	which	can	
objectively	compare	two	therapy	regimes	in	terms	of	economic	benefits	derived	by	
stakeholders,	can	be	applied	to	evaluate	the	economic	value	of	competing	treatment	regimes.	
	
1.	Introduction	
	
According to National Cancer Institute (NCI) an estimated 1.7 million new cases of cancer will 
be diagnosed in the United States in 2016 and 600,000 people will die from the disease. In 2010 
alone, US expenditures for cancer care totaled nearly $125 billion and are estimated to reach 
$156 billion in 20201. According to the same institute, compared to different types of common 
cancers, breast cancer is estimated to have the highest number of incidences and deaths in 2016, 
246660 and 40450 respectively1. The most common cause of hereditary breast cancer is an 
inherited mutation in the BRCA1 and BRCA2 genes2,3. These genes encode for proteins, which 
restrict abnormal cell growth in normal cells. A version of these genes carrying mutations 
prevents them from doing their normal housekeeping functions which leads to development of 
cancer. When breast cancer patients were analyzed, genomic testing on breast cancer tumors 
revealed other important genes directly involved in cancer development. One of the more 
prominent ones is ERBB2 gene. Recent studies, particularly concentrated on the HER2 or ERBB2 
gene which makes HER2 proteins4-7, have revealed the critical role this protein plays in tumor 
growth. HER2 proteins function as receptors on the breast cells. In a normal functioning cell, 
HER2 receptors control the breast cell growth, division, and self-repairs. But it has been shown 
that in about 25-30% of breast cancers, the HER2 gene malfunctions by making multiple copies 
of it, an event known as HER2 gene amplification. All these extra HER2 genes lead to 
overexpression of HER2 protein causing breast cells to grow and divide in an uncontrolled 
manner. Breast cancers with HER2 gene amplification or HER2 protein overexpression are 
termed as HER2-positive in the pathology report. HER2-positive breast cancers tend to grow 
faster and are more likely to spread and come back compared to HER2-negative breast cancers4,8-
10. In recent years, biopsies have confirmed that approximately 30% of breast cancer patients 
have been identified to carry this mutation, making it one of the most sought after drug target5,11. 
Currently there are four different molecular diagnostic methods to ascertain the presence of 
HER2 mutation. 1) IHC test (ImmunoHistoChemistry)	12: The IHC test determines if there is 
excessive HER2 protein in the cancer cells. The results are interpreted as follows: 0 (negative), 
1+ (also negative), 2+ (borderline), or 3+ (positive — HER2 protein overexpression). 2) FISH 
test (Fluorescence In Situ Hybridization)	13: The FISH test determines if there are extra copies of 
the HER2 gene in the cancer cells. The results are interpreted as positive (HER2 gene 
amplification) or negative (no HER2 gene amplification). 3) SPoT-Light HER2 CISH test 
(Subtraction Probe Technology Chromogenic In Situ Hybridization)	14: The SPoT-Light test 
determines if there are extra copies of the HER2 gene in the cancer cells. The results are 
interpreted as positive (HER2 gene amplification) or negative (no HER2 gene amplification), and 
4) Inform HER2 Dual ISH test (Inform Dual In Situ Hybridization)	15: The Inform HER2 Dual 
ISH test determines if there are extra copies of the HER2 gene in the cancer cells. The results are 
interpreted as positive (HER2 gene amplification) or negative (no HER2 gene amplification). 
Though There is no agreement on the best method for determining HER2 status, out of the four 
testing methods mentioned above, FISH and IHC are the most widely used for clinical diagnosis 
and recommended by all current national testing guidelines. While IHC tests for detect HER2 
receptor overexpression, FISH measures the level of HER2 gene amplification. Results observed 
with IHC assays vary a lot and there are several factors that may contribute to the variations 
including sensitivity and specificity of the antibodies, use of antigen retrieval techniques, 
antibody dilution, pH of buffer, and sensitivity and specificity of the detection system. On the 
other hand, FISH techniques has been shown to be a highly reproducible technique for HER2 
testing, allowing prolonged storage of paraffin blocks that does not affect its sensitivity16. 
Generally, only cancers that test positive in these tests respond to the drugs targeting HER2-
positive breast cancers. Over the years, the primary line of therapy for targeting breast cancer has 
been chemotherapy17,18. Several studies have shown that targeting the HER2 mutation by adding 
Trastuzumab or Herceptin to the chemotherapy drug cocktail have improved survival and relapse 
after initial treatment11,18-24. In spite of its widespread use, no formal study has been conducted 
on the cost effectiveness of covering the molecular diagnostic tests that lead to the prescription 
of this drug in the United States. Participants in clinical studies the CMS relies on for coverage 
determinations differ substantially from the Medicare population. Most of the times sufficient 
data is not available on relevant subgroup populations in order to make coverage decisions25. In 
many cases it has been observed that some of the scenarios that were deemed appropriate by 
medical service providers were conflicting with the clinical requirements of many payers, 
including the Medicare National Coverage Determination (NCD) 26. Some researchers have put 
the blame on federal advisory committees and the intra-committee dynamics for the discrepancy 
in coverage decision27. Premarket evidence for drugs and molecular diagnostics has limited 
ability to assure reproducible long-term outcomes, efficacy in different practice settings, and 
benefits and risks in underrepresented populations in trials which makes coverage determination 
challenging. These limitations particularly affect personalized medicine, where data is essential 
in determining the effects of a new drug or device in particular subgroups of patients based on 
preferences, genomics, and other relevant clinical factors28. This uncertainty makes it important 
to evaluate of costs and benefits of prescribing Herceptin treatment based on molecular 
diagnostic results. Though several recent studies on evaluating the clinical utility29and costs 30-32 
of using Herceptin with chemotherapy have been conducted, they do not include a cost 
effectiveness analysis by comparing treatment regimes across cross sectional patient data. A 
recent study performed on Canadian breast cancer patient data to measure cost effectiveness of 
Herceptin has used only three health states along with Canada specific EFS data which is not 
directly portable under US Medicare reimbursement framework33. Few other studies to model 
economic costs of cancer exist but they too use a European payer framework for evaluation of 
costs making direct application to US cancer patient data difficult34,35. Literature on modeling 
caner costs is abound with different methodologies such as discrete event simulation36, Markov 
chain37-39, and web crawler approaches38. The first two methods largely depend on accurately 
predicting the probabilities and rates of cancer incidence, treatments and population dynamics 
which can be a herculean task given changing patient characteristics and advancements in 
diagnostic technologies. Methodologies that depend upon extracting information from the 
Internet can produce inaccurate results due to lack of curated clinical data. Researchers have also 
developed many cancer specific models including thyroid40, cervical41, lung35,42,43, breast44, and 
colorectal35 cancers. But they all fall short in calculating per patient cost savings to be 
universally applicable. Hence we propose a novel method, which uses Medicare patient data 
from the Surveillance, Epidemiology, and End Results (SEER) database to model the 
incremental cost savings by using mutation specific drug treatment in addition to 
chemotherapy45. In the following study, we estimate per patient savings by comparing cancer 
free survival in two groups of patients harboring HER2 mutation, one that were treated with 
Herceptin along with chemotherapy versus those treated with chemotherapy alone. Though the 
model evaluates benefits of a breast cancer specific mutation-targeting drug, the methodology 
can be extended to evaluate other mutation specific treatments. 
 
2. Methods 
As shown in figure 1, we have developed a model to compare Herceptin usage in breast cancer 
patients. We start by estimating the number of patients who did and did not receive Herceptin 
treatment. In the next step we estimate the incremental survival and the incremental costs 
associated with Herceptin usage in this patient population. Finally we estimate the incremental 
economic value of the life-years saved for BC patients when treated with Herceptin.  
Fig 1. Flow of per-patient cost savings calculations. 
2.1 Patient Selection 
The National Cancer Institute collects incidence and population data associated by age, sex, race, 
year of diagnosis, and geographic areas. The first recordings started in 1973 and the database 
consists every single reported cancer incidence from 9 cancer registries across the US45. From the 
comprehensive SEER patient database, we selected only those breast cancer patients that harbor 
Her2 gene mutation, otherwise referred as “HER2 positive” in the database (“DerHer2Recode”)*. 
In addition to the HER2 status, the dataset consists of HER2 summary result column, which was 
not a required data item for every breast cancer case diagnosed before 2010. As a result we were 
																																																						
* The SEER database also defines breast cancer subtypes (“BrstSubType”) by joining hormone receptor (HR which is a 
combination of estrogen receptor [ER] and progesterone receptor [PR]) and HER2 status45. This variable is useful in determining 
HER2 status and facilitating the analysis of trends in breast cancer molecular subtypes. But due to high correlation between 
breast subtypes variable and derived HER2 recode variable (0.996), we decided to use only the HER2 recode variable, as it is 
easy to calculate and interpret.  
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only interested in cases having incidence date of 2010 or later as cases before 2010 have not 
reported the HER2 status of BC patients.  For the 110,800 breast cancer cases diagnosed 2010 
onwards, the number of patients with positive HER2 mutation was 12,255.  We have considered 
the possibility that some patients will test HER2 positive even if they're actually HER2 negative 
and vice versa or in other words the possibility of Type I/II errors. Before applying the recoding 
algorithm for the cases with missing HER2 summary information, NCI has first applied it to 
cases for which directly coded HER2 summary information was available to assess agreement of 
the derived results to the coded results. Then the results obtained using these two approaches 
were compared, and more than 97% similarity was found45. This leads us to believe that any 
Type I/II errors in the dataset are low enough not to affect the overall analysis. 
Though Herceptin is generally used with patients harboring the HER2 mutation and breast 
cancer being in metastatic stage or has spread to other parts of the body, in 2006, it was approved 
by FDA as part of a treatment regime for the adjuvant treatment of HER2 positive breast cancer. 
Thus we have included both the patient populations, in situ and metastatic stage patients, in this 
study46.  
2.2 Herceptin Usage Determination 
We divided the patient population into two groups, one treated with Herceptin and the other 
without. As we did not have access to the SEER-Medicare linked dataset and the SEER*Rx 
database, patient populations for both the groups were estimated using proxies for Herceptin 
usage based on the information provided in the SEER data. We have used the following method 
to estimate whether Herceptin was used as part of the therapy.  
According to various sources, for uninsured patients, the cost of Herceptin can exceed $70000 
per year or $5833 per month on the higher side while it can be as low as $54,000 per year or 
$4500 per month with some insurance providers47-50.  We have used a conservative cost estimate 
of $70000 per year or $5833 per month for Herceptin treatment. Due to its high price, Herceptin 
is unaffordable to the uninsured patient population. Medicare part B covers 80% of the drug cost 
making it affordable to the population covered with some form of insurance51,52. Hence, as a 
proxy for Herceptin usage, we have considered patients exhibiting HER2 mutation, having any 
type of insurance (Medicare, Medicaid, or private), and breast cancer incidence date 2010 and 
after. Similarly patients without any insurance coverage with identical HER2 status were 
grouped to create a population not treated with Herceptin.  
2.3 Costs 
Literature has shown that in clinical practice, treatment lengths of Herceptin vary due to large 
number of factors. Some oncologists, including scientists at Roche, maker of Herceptin, 
prescribe Herceptin for one full year. But in reality, most of the time, the treatment is effective 
only when used less than 3 months as the patients build resistance to the drug. Also patients may 
not survive the entire length of treatment as everyone responds differently to the drug. In 
addition, patients with HER2 mutation have relatively low survival rate as the mutation makes 
the tumor more aggressive. Due to these variations, it is unreasonable to assume that the average 
patient, who received Herceptin, received it for one full year. But, in absence of actual Herceptin 
usage data, we have used one year as the average length of Herceptin treatment. Generally, 
Herceptin comes in 400ml vials and is delivered in 40ml quantities with chemotherapy drug 
cocktail. Recently CMS has issued warnings concerning Herceptin billing. Hospitals and cancer 
centers have consistently charged the CMS for whole 400 ml bottle regardless of actual usage 
and CMS policy dictates that the exact amount of Herceptin used for individual patient must be 
billed. Hence we believe that the marginal cost of whole Herceptin treatment, which though for a 
year, will overstate the actual cost of the drug to the CMS. Hence, for cost calculations, we have 
used a conservative estimate of $5833 for one month’s Herceptin supply allowing fractional drug 
usage wherever necessary.  
Though it is difficult to put a dollar amount on the value of each life year for cancer patients, 
literature abounds with various cost of additional life year and in 2016 dollar, ranges from 
$100,000 to $165,000, according to some authors53,54. This leads to a cost of $8,333 to $13,750 
per month for individual cancer patient. Again, in this case, we have used the most conservative 
estimate of $8,333 per month.  
The last of the cost estimates we calculated is for the molecular diagnostic tests that determine 
existence of HER2 mutation in the BC tumor. Currently FISH test is the gold standard used for 
testing the presence of HER2 mutation and costs between $537 and $575 according to various 
providers55,56. FISH test also has a well-established Medicare reimbursement framework in place. 
Hence going with the conservative estimate, we have used the cost of $575 for the FISH test in 
our calculations 
 
 
 
3. Data 
The inputs for the model were derived from real world, heterogeneous, population-based data 
sources. HER2 status, survival, and insurance coverage were derived from the Surveillance, 
Epidemiology, and End Results (SEER) cancer registry data. The National Cancer Institute 
collects incidence and population data associated by age, sex, race, year of diagnosis, and 
geographic areas. The first recordings started in 1973 and the database consists every single 
reported cancer incidence from 9 cancer registries across the US.  According to the program 
website, the SEER 9 registries are Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, 
San Francisco-Oakland, Seattle-Puget Sound, and Utah.  Data are available for cases diagnosed 
from 1973 and later for these registries with the exception of Seattle-Puget Sound and Atlanta. 
The Seattle-Puget Sound and Atlanta registries joined the SEER program in 1974 and 1975, 
respectively. The total number of cases documented in the SEER database is 9,176,963 with 
8,234,845 cases being malignant. Cases are recorded for 9 different cancer types. The November 
2015 submission of the breast dataset consists of information on 135 variables for 769,261 
patients diagnosed between 1973 and 2013. Table 1 & 2 shows the summary statistics for the 
individual groups: treated and untreated. 
Variable/Statistic Mean SD Median IQR Range 
Age 58.14 13.80 57 48-67 18-100 
Survival Month 21.25 13.77 21 9-33 0-47 
Table 1. Age & survival statistics for patients with breast cancer incidence harboring HER2 mutation, diagnosed after 2009, and 
received Herceptin treatment from Medicare’s cancer registry database. 
 Variable/Statistic Mean SD Median IQR Range 
Age 49.1 9.13 50 42-57 25-64 
Survival Month 18.76 13.34 17 8-28 0-47 
Table 2. Age & survival statistics for patients with breast cancer incidence harboring HER2 mutation, diagnosed after 2009, and 
did not receive Herceptin treatment from Medicare’s cancer registry database. 
Various other sources of data have been used for calculating the cost of treatment and cost of life 
years saved as described in the methods section. The primary determinant of life years saved is 
the number of months the patients have survived after initial treatment and comes directly from 
the SEER database. While figures for Herceptin costs come from well-established medical drug 
databases and insurance providers, cost of a life year is taken from previously published 
research, which have meticulously developed methodologies to accurately estimate the economic 
value of each additional year in cancer patients’ life.  
Cost of molecular diagnostic tests is referred directly from vendor websites providing these 
services. In each case, the most conservative cost estimate is used for the analysis. 
 
4. Results 
As described in the methods section, using the ‘survival months’ data from the SEER database, 
we calculated the median survival for both the treated and untreated groups of patients.  As seen 
in table 1 and 2, the patient group treated with Herceptin had median survival of 21 months 
compared to 17 months for patients that did not receive Herceptin treatment.  
We have considered several factors that might affect the survival of HER2+ BC patients. As 
shown in table 3, insurance status and age at diagnosis are significant predictors of survival while 
sex, race and marital status are weak predictors at best.  
Coefficients: Estimate Std. Error t value Pr(>|t|)     
Intercept       22.68    0.82   27.57 < 0.001 
Age at Diagnosis -0.067 0.01    -7.29  < 0.001 
Insurance status 0.81    0.23 3.55 < 0.001 
Sex     0.04    1.57   0.03 < 1 
Race -0.015  0.01      -1.64  < 0.1 
Marital status -0.001 0.07 -0.01 < 0.1 
Table 3. Results of linear model when survival months are regressed on various parameters. 
Hence we can omit the confounding variables, which are not statistically significant to model a 
regression fit using only the Age at diagnosis and Insurance status. The model results, which are 
identical to the previous model, are shown in table 4. 
 
 
 
Coefficients: Estimate Std. Error t value Pr(>|t|)     
Intercept       22.68    0.82   27.57 < 0.001 
Age at Diagnosis -0.067 0.01    -7.29  < 0.001 
Insurance status 0.81    0.23 3.55 < 0.001 
Table 4. Results of linear model when survival months are regressed on age and insurance status. 
Going forward, we first created a dummy variable “Treat” which takes into account the 
insurance status and age at diagnosis indicating whether a particular patient received Herceptin 
treatment or not.  A value of 0 indicates that the patient did not receive Herceptin treatment while 
a value of 1 indicates that Herceptin treatment was received. A linear model to estimate 
difference in the mean survival confirms that the treated group has an average incremental 
survival of 2.5 months, which is statistically significant at 5%. The results are shown in table 5.  
Coefficients: Estimate Std. Error t value Pr(>|t|)     
Intercept       18.7565    0.9905   18.936    < 0.001 
Treatment 2.4931    0.9986    2.497    < 0.05 
Table 5. Results of linear model when survival months are regressed on binary treatment variable. 
Next, we have assessed the robustness of the model using quantile regression fit to estimate the 
effects of outliers and calculate difference in the median survival months between treated and 
untreated groups. As indicated by the Treatment variable, the difference in median survival for 
the two groups is 4.43 months, which is statistically significant at 5%. Other confounding factors 
such as Race, Sex, and Marital status have minuscule effects on the median survival, which is 
not statistically significant. The results of quantile regression fit are presented in table 6. 
Coefficients: Estimate Std. Error t value Pr(>|t|)     
Intercept       22.13 3.52 6.27 < 0.001 
Treatment 4.43 1.41 3.12 < 0.05 
Race    -0.02  0.01 -1.5 < 1 
Sex -0.54 1.55 -0.35 < 1 
Marital Status    0.18 0.11 1.53 < 1 
Table 6. Results of quantile regression for survival months vs. binary treatment variable along with other confounding variables. 
Hence we have used a quantile regression model with Treatment as the only x variable. The 
results of this model are shown in table 7. 
Coefficients: Estimate Std. Error t value Pr(>|t|)     
Intercept       17    1.27   13.38 < 0.001 
Treatment 4 1.28 3.12 < 0.05 
Table 7. Results of linear model when survival months are regressed on binary treatment variable. 
 Lastly, we have used propensity score model, which is used to improve parametric statistical 
models and reduce model dependence by preprocessing data with semi-parametric and non-
parametric matching methods, to assess whether the difference in survival months between 
treated and untreated groups is stable. We have used the ‘MatchIt’ package for R developed by 
Stuart et. al57,58. The matched dataset produced by their algorithm, using nearest matching 
method, is then used to regress survival months on the treatment variable. The results indicate 
that the difference in the mean survival of the two matched groups is statistically significant at 
5%. The results are presented in table 8. When other confounding variables such as Race, Sex, 
and Marital status are regressed against survival, sex of the patient seems to have a huge negative 
effect on the survival but the result is not statistically significant. Race and Marital status have a 
small effect on the overall survival but are not statistically significant. The only variable that has 
statistically significant effect on survival is the dummy treatment variable, which indicates 
whether the patient received Herceptin treatment, or not. 
 
Coefficients: Estimate Std. Error t value Pr(>|t|)     
Intercept       32.65    27.47 1.19 < 1 
Treatment 2.94   1.39 2.11 < 0.05 
Race       -0.01 0.04 -0.34 < 1 
Sex -7.35 13.69 -0.53 < 1 
Marital Status 0.36 0.38 0.95 < 1 
Table 8. Results of linear regression for survival months of matched data vs. binary treatment variable along with other 
confounding variables. 
Hence we have used only the treatment variable to predict survival as shown in table 9. 
Coefficients: Estimate Std. Error t value Pr(>|t|)     
Intercept       18.75    0.97   19.16    < 0.001 
Treatment 3.07    1.38 2.22 < 0.05 
Table 9. Results of linear regression for survival months of matched data vs. binary treatment variable. 
This confirms that the difference in the survival for the treated and untreated groups is 
statistically significant and robust. We have considered using trimmed mean instead of average 
survival owing to the fact that Herceptin is not a maintenance drug. As median survival is a fully 
truncated mean and more stable than simple mean, we have used it as a survival estimator in the 
model. From the above models, the additional median months survived or the incremental 
survival rate for patients treated with Herceptin is 4 months compared to the untreated group.  
Using the methodology defined in earlier section, we calculated the incremental costs of 
Herceptin treatment by adding Herceptin cost for one year of treatment and one time cost of the 
FISH test, which equals $70,575. The incremental benefit, which is the cost of incremental life 
years added, calculated using cost estimates mentioned in the methods section are $33,332. This 
puts the incremental cost savings of Herceptin treatment at -$37,243 per patient. 
 
5. Conclusion 
In this study we have used the SEER database to calculate the incremental per patient cost 
savings by using Herceptin along with standard chemotherapy drugs. Using the combination of 
insurance coverage and HER2 mutation status, as a proxy for Herceptin usage, we were able to 
calculate the per-patient cost savings, by using Herceptin, to be -$37,243. These negative cost 
savings are the result of extending the overall survival of breast cancer patients with HER2 
mutation by just four months with Herceptin. Substituting the relatively inexpensive FISH test 
for confirming positive HER2 mutation with more expensive test panels, which cost in the range 
of $4500 without insurance, will not affect the overall outcome of this study. Based on medical 
literature analyzing QALY assessment the threshold of cost effectiveness of medical 
interventions is thought to be $50  000–$100  000 in the US59. Given the moderate side effects 
of Herceptin treatment, which primarily includes some minor cardiovascular complications 
compared to chemotherapy60-62, we think a quality adjustment between the treated and untreated 
groups is not necessary. Hence, this study raises valid questions about the cost effectiveness of 
molecular diagnostic tests in identifying mutations in the breast cancer tumor that can be targeted 
with immunotherapy and extend the overall survival of BC patients. The generalized cost 
effectiveness model proposed in this study can be easily applied to evaluate the effectiveness of 
any molecular diagnostic test and its companion targeted therapy.  
In the future, the accuracy of this study can be further enhanced by incorporating the pricing data 
from Medicare*Rx which records the actual price paid for Herceptin by the CMS and extracting 
details on the chemotherapy treatment information from the Medicare Linked Database.  Gaining 
access to these databases requires a well-funded proposal from well-established institutions 
clearly showing its benefit to the CMS. Due to the limited scope of this modeling study, it does 
not fulfill the data access requirements in its present form. But the encouraging results obtained 
from this exercise can be used as a foundation for building sophisticated models in the future and 
to make a case for more advanced studies to be designed based on the Medicare*Rx database. 
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